




Investment Objective

To invest in the global healthcare sector with the objective of achieving a high level of capital growth. In order to achieve its investment objective, the Company invests worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector. It uses gearing, and derivative transactions to enhance returns and mitigate risk. Performance is measured against the MSCI World Health Care Index (net total return, sterling adjusted).

Five Year Performance (%)

Past performance is not a guide to future performance. The value of investments and the income from them may fall as well as rise and is not guaranteed; An investor may receive back less than the original amount invested.



Share Price (total return) +153.9%

Net Asset Value per share (total return) +144.2%

Benchmark: MSCI World Health Care Index (net total return; sterling adjusted) +92.4%

Source: Morningstar, Index - Bloomberg

Commentary

In July the NAV per share was up 4.2%, the share price was up 4.3%, and the MSCI World Health Care Index was up 6.7%.

July proved to be a strong month for global healthcare equity returns. Second quarter earnings, for the most part, exceeded expectations, particularly for large cap pharmaceutical stocks, further stoking a momentum trade that commenced earlier in the month. Additionally, unexpected positive news in the development of a novel drug for the treatment of Alzheimer's disease also buoyed share prices. Macro concerns overhanging the sector, such as the politics of U.S. drug pricing, clearly took a back seat to industry fundamentals and generalist sentiment in the month.

The Company's performance in July was strongly positive but underperformed the benchmark. There were some notable factors that impacted relative performance in the month, including (1) stock picking in medical devices and biotechnology stocks and (2) allocation effects in emerging markets, mid cap biotechnology, and large cap pharmaceuticals.

The largest component to the negative alpha generated in July was our underweight exposure to large cap pharmaceutical stocks. Second quarter results for these global companies mostly beat expectations, in particular sales performance in the U.S. where expectations were guarded. Notably, the NYSE Arca Pharmaceutical Index advanced +8.3% (sterling terms) in the month, the 5th largest monthly move in the "DRG" this century. Relative underperformance was also exacerbated by our overweight in mid cap biotechnology stocks, which were collectively flat on the month, significantly lagging the benchmark.

The commentary continues on page 3.

Any opinions on individual stocks are those of the Company's Portfolio Manager and no reliance should be given on any such views. Any research in this document has been procured and may have been acted upon by OrbiMed Capital LLC for its own purposes. The results are being made available to you only incidentally. The views expressed herein do not constitute investment or any other advice and are subject to change. They do not necessarily reflect the views of Frostrow Capital LLP and no assurances are made as to their accuracy.

Risk Warnings

This document is for information purposes only and does not constitute an offer or invitation to purchase shares in the Company and has not been prepared in connection with any such offer or invitation. Before investing in the Company, or any other investment product, you should satisfy yourself as to its suitability and the risks involved, and you may wish to consult a financial adviser.

Any return you receive depends on future market performance and is uncertain. The Company does not seek any protection from future market performance so you could lose some or all of your investment. For information on the principal risks the Company is exposed to please refer to the Company's Annual Report or Investor Disclosure Document available at www.worldwidewh.com.

Shares in the Company are bought and sold on the London Stock Exchange. The price you pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company. Usually, at any given time, the price you pay for a share will be higher than the price you could sell it.

The Company has increased its exposure to investments, via the use of an overdraft facility and derivatives and this could potentially magnify any losses or gains made by the Company. The Annual Report and Investor Disclosure Document, available on the Company's website, include further details on the use of, and exposure to, derivatives.

Biographies

Sven H. Borho, CFA, is a founder and Managing Partner of OrbiMed. Mr. Borho heads the public equity team and he is the portfolio manager for OrbiMed's public equity and hedge funds. Mr. Borho has been a portfolio manager for the firm's funds since 1993 and has played an integral role in the growth of OrbiMed's asset management activities. Mr. Borho started his career in 1991 when he joined OrbiMed's predecessor firm as a Senior Analyst covering European pharmaceutical firms and biotechnology companies worldwide. Mr. Borho studied business administration at Bayreuth University in Germany and received a M.Sc. (Econs.), Accounting and Finance, from The London School of Economics; he is a citizen of both Germany and Sweden.

Trevor M. Polischuk, Ph.D., is a Partner at OrbiMed focused on the global pharmaceutical industry. Trevor joined OrbiMed in 2003 and became a Partner in 2011. Previously, he worked at Lehman Brothers as a Senior Research Analyst covering the U.S. pharmaceutical industry. Trevor began his career at Warner Lambert as a member of the Global Marketing Planning team within Parke-Davis. Trevor holds a Doctorate in Neuropharmacology & Gross Human Anatomy and an M.B.A. from Queen's University, Canada.

Portfolio Manager Profile

OrbiMed Capital LLC (OrbiMed) is owned by six principals, including Sven Borho who have between them many years' experience of investing in the pharmaceutical, biotechnology and healthcare sectors. The U.S. based company has over 90 investment professionals who carry out extensive research, involving company visits and developing an understanding of the commercial and scientific prospects for individual drugs. OrbiMed is registered as an investment adviser under the U.S. Securities and Exchange Commission (SEC). SEC registration does not imply a certain level of skill or training.

Investment Policy

The Company offers a superior UK-listed opportunity for capital appreciation through a diversified portfolio of worldwide pharmaceutical, biotechnology, healthcare equipment, healthcare technology and healthcare services companies. The Portfolio Manager seeks to reduce risk through extensive fundamental research, worldwide exposure, position limits, and balanced market capitalisations. The Company's investment objective also allows gearing, through borrowing, of up to 20% of net assets and a net exposure to derivative investments (excluding swaps) of up to 5% of the portfolio. Equity swaps may also be used, counterparty exposure here is limited to 12% of the portfolio at the time of acquisition.

(Discount) / Premium Control Mechanism

The Directors have adopted an active discount management policy to establish and support an improved rating in the Company's shares through the use of share buybacks, with a view to limiting the discount to the ex income NAV per share at which the shares trade to no more than 6%. Shares bought back may be held in treasury for reissue at later dates at not more than the discount at which they were purchased, and in any event at a discount no greater than 5% to the prevailing cum income net asset value per share. Any shares left in treasury are cancelled around the time of the AGM. In order to stop the share price trading at a significant premium to the NAV per share, the Company has the ability to issue new shares at a 0.7% premium to the cum income NAV per share.

Worldwide Healthcare Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers ("IFAs") to retail private investors. The shares are excluded from the Financial Conduct Authority's ("FCA's") restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.

10 Largest Holdings as at 31 July 2018*

Name	Region	Total
Alexion Pharmaceuticals	North America	5.1
Biogen	North America	4.5
Merck & Co	North America	4.3
Boston Scientific	North America	4.1
Allergan	North America	3.5
Novo Nordisk	Europe	3.3
Vertex Pharmaceuticals	North America	3.0
Wright Medical	Europe	3.0
Celgene	North America	2.3
Anthem	North America	2.2
Total		35.3

Sector, Geographical** & Asset Class Breakdown at 31 July 2018*

Biotechnology	32.0	North America	66.1	Equities	90.6
Pharmaceutical	29.9	Europe	18.1	Equity Swaps	6.7
Healthcare Equipment/Supplies	15.1	Emerging Markets	9.7	Fixed & Variable	2.1
Healthcare Providers/Services	12.3	Asia	6.1	Options	0.6
Life Sciences/Tools & Services	4.9	Total	100.0	Total	100.0
Emerging Markets Baskets	3.1				
Fixed & Variable Interest	2.1				
Other Baskets	0.6				
Total	100.0				

*Calculation based on economic exposure and expressed as a % of the total economic exposure. This includes all derivatives as an economically equivalent position in the underlying holding.

**Geographical analysis based on country of incorporation.

Source: All portfolio information sourced from Frostrow Capital LLP.

Discrete Performance – Calendar Years (%)

Percentage Growth	2013	2014	2015	2016	2017	YTD
NAV	44.3	38.8	19.1	5.2	16.5	11.8
Share Price	47.1	39.6	13.9	10.1	20.7	9.9
Benchmark	33.6	25.6	12.7	11.2	9.4	11.0

Standardised Discrete Performance (%)

Percentage Growth 12 Month Return	Jul 13- Jul 14	Jul 14- Jul 15	Jul 15- Jul 16	Jul 16- Jul 17	Jul 17- Jul 18
NAV	19.6	51.4	8.0	10.8	12.7
Share Price	15.4	54.4	5.7	20.9	11.5
Benchmark	8.7	33.0	13.0	5.4	11.8

Past performance is not a guide to future performance. The value of investments and the income from them may fall as well as rise and is not guaranteed. An investor may receive back less than the original amount invested.

Source: NAV (total return; fully diluted) & share price (total return) – Morningstar. Benchmark - Bloomberg.

Awards

Winner: Investment Week, Investment Company of the Year 2016, Specialist (including Hedge Funds) Category

Important Information

Worldwide Healthcare Trust PLC (the Company) is a public limited company whose shares are premium listed on the London Stock Exchange (LSE) and is registered with HMRC as an investment trust.

The Company has an indeterminate life, although shareholders consider and vote on the continuation of the Company every five years (the next such vote will be held in 2019).

This financial promotion is issued by Frostrow Capital LLP which is authorised and regulated by the Financial Conduct Authority ("FCA").

The MSCI information (relating to the Benchmark) may only be used for your internal use, may not be reproduced or disseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an "as is" basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the "MSCI Parties") expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation lost profits) or any other damages. (www.msci.com).

Fast Facts as at 31 July 2018

AIC Sector	Biotechnology & Healthcare
Launch Date & appointment of Portfolio Manager	April 1995
Annual Management Fee (payable by the Company): 0.65% of net assets plus 0.30% of market cap. up to £150m, in the range £150m to £500m 0.2%; in the range £500m to £1bn 0.15%; in the range £1bn to £1.5bn 0.125%; over £1.5bn 0.075% plus £57,500	
Performance Fee	See Annual Report for details
Ongoing charges*	0.9%
Continuation Vote	2019 AGM and every 5 th AGM thereafter
Year / Half Year	31 March / 30 September
Capital Structure	50,013,778 shares

*Calculated at the financial year end, includes management fees and all other operating expenses, and excludes performance fees.

Trust Characteristics

Number of Holdings	102
Net Assets (£m)	1,377.6
Market Capitalisation (£m)	1,385.4
Dividends	Provisional payment dates: January & July
Indicative Yield	0.6%
Gearing	8.3%
Leverage**	Gross 118.2% Commitment 116.9%
Share Price (p)	2770.00
NAV(p) (cum income)	2754.36
Premium / (Discount)	0.6%

** The Board has set the maximum leverage limit for both the Gross and the Commitment basis at 140% of the Company's Net Asset Value.

Codes

Sedol	0338530
ISIN	GB0003385308
Legal Entity Identifier (LEI)	5493003YBCY4W1IMJU04
Global Intermediary Identification Number (GIIN)	FIZWRN.99999.SL.826
Bloomberg	WWH LN
Epic	WWH

How to Contact Us

Frostrow Capital LLP
25 Southampton Buildings, London, WC2A 1AL
Tel.: 0203 0084910
Fax: 0203 0438889
Website: www.frostrow.com
Email: info@frostrow.com

Continued from page 1..

Additionally, emerging market healthcare share prices were weak in the month. Specifically, the China stock market reacted negatively to the worsening U.S./China trade tension and the sharp depreciation of Chinese currency. Share price weakness was heightened by intensive profit taking in the healthcare sector.

Finally, two stocks of note were materially weak in the period and were marked detractors. The medical device company, **Nevro** was hit with a treble of negative news (a high profile sell side downgrade, negative patent litigation headlines, and a departure of a key executive). Shares in **Puma Biotechnology** sold off given investor concerns ahead of the company's second quarter report in August.

That said, we would like to note critical drug development news from July. Partners **Biogen** and **Eisai** disclosed ground breaking Phase II data in the treatment of Alzheimer's disease. Whilst not without controversy, the data for "BAN2401" was consistent of the amyloid hypothesis and were supportive of further development of this antibody to combat this terrible disease. These two stocks were the largest contributors in the month. Importantly, we believe that Alzheimer's disease will continue to be a strategic investment theme for multiple stocks going forward.

